NUMBERS NEEDED TO TREAT AND COSTS PER IMPROVED OUTCOME AMONG TREATMENTS FOR MYASTHENIA GRAVIS

被引：0
|
作者：
Qi, C. [1 ]
Wang, J. [2 ]
Yang, H. [2 ]
Gelinas, D. [1 ]
Brauer, E. [1 ]
Du, M. [2 ]
Sun, R. [2 ]
Phillips, G. [1 ]
机构：
[1] Argenx Inc, Boston, MA USA
[2] Anal Grp Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE121
引用
收藏
页码：S358 / S358
页数：1
相关论文
共 24 条
  • [1] Numbers Needed to Treat and Costs Per Improved Outcome Among Treatments for Myasthenia Gravis
    Hughes, Tom
    Qi, Cynthia
    Wang, Jessie
    Yang, Hongbo
    Gelinas, Deborah
    Brauer, Edward
    Du, Mandy
    Sun, Rochelle
    Phillips, Glenn
    NEUROLOGY, 2022, 99 (23) : S38 - S39
  • [2] Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis
    Armstrong, April
    Betts, Keith
    Li, Junlong
    Sundaram, Murali
    Wu, Eric
    Signorovitch, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB261 - AB261
  • [3] Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan
    Imafuku, Shinichi
    Nakano, Ataru
    Dakeshita, Hidetoshi
    Li, Junlong
    Betts, Keith A.
    Guerin, Annie
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (01) : 24 - 31
  • [4] Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
    Armstrong, April W.
    Betts, Keith A.
    Signorovitch, James E.
    Sundaram, Murali
    Li, Junlong
    Ganguli, Arijit X.
    Wu, Eric Q.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (07) : 1325 - 1333
  • [5] Comparing the effectiveness of infertility treatments by numbers needed to treat (NNT)
    Comhaire, F.
    Decleer, W.
    ANDROLOGIA, 2012, 44 (06) : 401 - 404
  • [6] Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome
    Cortes-Vicente, Elena
    Alvarez-Velasco, Rodrigo
    Pla-Junca, Francesc
    Rojas-Garcia, Ricard
    Paradas, Carmen
    Sevilla, Teresa
    Casasnovas, Carlos
    Teresa Gomez-Caravaca, Maria
    Pardo, Julio
    Ramos-Fransi, Alba
    Lara Pelayo-Negro, Ana
    Gutierrez-Gutierrez, Gerardo
    Turon-Sans, Janina
    Lopez de Munain, Adolfo
    Guerrero-Sola, Antonio
    Jerico, Ivonne
    Asuncion Martin, Maria
    Dolores Mendoza, Maria
    Moris, German
    Velez-Gomez, Beatriz
    Garcia-Sobrino, Tania
    Pascual-Goni, Elba
    Reyes-Leiva, David
    Illa, Isabel
    Gallardo, Eduard
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2022, 9 (02): : 122 - 131
  • [7] DIRECT AND INDIRECT COSTS AMONG EMPLOYED PATIENTS WITH MYASTHENIA GRAVIS IN SWEDEN
    Cai, Q.
    Zhang, Q.
    Borsum, J.
    Batista, A.
    Kunovszki, P.
    Isheden, G.
    Heerlein, K.
    VALUE IN HEALTH, 2023, 26 (06) : S133 - S133
  • [8] Treatments, Healthcare Utilization and Costs in Newly Diagnosed and Preexisting Myasthenia Gravis Patients in Sweden
    Batista, A.
    Cai, Q.
    Borsum, J.
    Kunovszki, P.
    Zhang, Q.
    Isheden, G.
    Heerlein, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 351 - 351
  • [9] Influence of number needed to treat costs and outcome on preferences for a preventive drug
    Nexoe, J
    Kristiansen, IS
    Gyrd-Hansen, D
    Nielsen, JB
    FAMILY PRACTICE, 2005, 22 (01) : 126 - 131
  • [10] IMMUNOSUPPRESSIVE TREATMENTS - THEIR EFFICACY ON MYASTHENIA-GRAVIS PATIENTS OUTCOME AND ON THE NATURAL COURSE OF THE DISEASE
    CORNELIO, F
    ANTOZZI, C
    MANTEGAZZA, R
    CONFALONIERI, P
    BERTA, E
    PELUCHETTI, D
    SGHIRLANZONI, A
    FIACCHINO, F
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 681 : 594 - 602
123